Trial reportAJR. American journal of roentgenology2020
Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.
Open access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in AJR. American journal of roentgenology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Comparison of the Pharmacokinetics of Gadolinium-Based and Iron Oxide-Based Contrast Agents inside the Lymphatic Structure using Magnetic Resonance Lymphangiography.Molecular imaging and biology · 2024Article
- Review
- Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.National science review · 2024Review
- Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.Nanoscale advances · 2024Review
- IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment.International journal of nanomedicine · 2023Review
- Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient Safety.International journal of nanomedicine · 2023Article
- Contrast-enhanced MR Angiography without Gadolinium-based Contrast Material: Clinical Applications Using Ferumoxytol.Radiology. Cardiothoracic imaging · 2022Article
- Recent Advancements in CT and MR Imaging of Prostate Cancer.Seminars in nuclear medicine · 2022Review
- The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery.Journal of nanobiotechnology · 2022Review
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis.Abdominal radiology (New York) · 2021Review
- The Role of Magnetic Resonance Imaging in (Future) Cancer Staging: Note the Nodes.Investigative radiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Baris TurkbeyMolecular Imaging Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10 Center Dr, Rm B3B85, Bethesda, MD 20892.
Marcin CzarnieckiMolecular Imaging Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10 Center Dr, Rm B3B85, Bethesda, MD 20892.
Joanna H ShihBiometric Research Branch, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD.
Stephanie A HarmonClinical Research Directorate, Frederick National Laboratory for Cancer Research, (Sponsored by the National Cancer Institute), Frederick, MD.
Piyush K AgarwalUrologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD.
Andrea B ApoloGenitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD.
Deborah E CitrinRadiation Oncology Branch, CCR, NCI, NIH, Bethesda, MD.
James L GulleyGenitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD.
Mukesh HarisinghaniDepartment of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Ravi A MadanGenitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD.
Adam R MetwalliDepartment of Surgery, Division of Urology, Howard University Hospital, Washington, DC.
Edmond PaquetteInova Medical Group Urology, Inova Fairfax Hospital, Fairfax, VA.
Peter A PintoUrologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD.
Soroush Rais-BahramiDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL.
Lindsay S RoweRadiation Oncology Branch, CCR, NCI, NIH, Bethesda, MD.
Bradford J WoodCenter for Interventional Oncology, CCR, NCI, NIH, Bethesda, MD.
Paula M JacobsCancer Imaging Program, CCR, NCI, NIH, Bethesda, MD.
Liza LindenbergMolecular Imaging Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10 Center Dr, Rm B3B85, Bethesda, MD 20892.
William DahutGenitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD.
Peter L ChoykeMolecular Imaging Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10 Center Dr, Rm B3B85, Bethesda, MD 20892.
Center for Cancer Research · USHarvard University · USHoward University Hospital · USInova Fairfax Hospital · USUniversity of Alabama at Birmingham · US
Funding
Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2MCenter for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7MProstate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2MTargeting mechanisms of radiation resistanceZIABC011552 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CITRIN, DEBORAH · 2014 to 2025
$12.2MBladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2010 to 2025
$9.4MThe Evaluation of Novel Therapeutics for Genitourinary MalignanciesZIASC010098 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI DAHUT, WILLIAM L. · 2009 to 2022
$7.6MLymphatic ImagingZIABC010654 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2020
$4.8MLymphatic ImagingZ01BC010654 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2005 to 2008
$1.1MInterventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0kCCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC010654Intramural NIH HHS Z99 CA999999NCI NIH HHS HHSN261200800001E
Abstract
PubMed holds no abstract for this paper.
Indexed as
Ferrosoferric OxideMagnetic Resonance ImagingAdultAgedAged, 80 and overHumansKidney NeoplasmsLymphatic MetastasisLymphographyMaleMiddle AgedProspective StudiesProstatic NeoplasmsRetrospective StudiesUrinary Bladder NeoplasmsFerrosoferric Oxidebladder cancerferumoxytolkidney cancerlymph nodeprostate cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.